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Introduction
In an aging population cardiovascular diseases, such as con-
gestive heart failure, have gradually become serious health 
challenges.  Congestive heart failure, generally defined as 
incapability of the heart to supply sufficient blood flow 
to meet the body’s needs, frequently leads to significantly 
adverse influences on physical and mental health, resulting in 
a markedly decreased quality of life and even death[1].  While 
cardiac glycosides, such as digoxin, digitoxin and ouabain, 
have been a cornerstone of the treatment of congestive heart 
failure for more than two centuries, severe side effects have 
been reported for these steroid-like compounds[2, 3].  The nar-
row therapeutic index (the margin between effectiveness 
and toxicity) of cardiac glycosides further limits their clinical 
applications[4].  The limited benefit with certain side effects of 
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the existing remedies has prompted investigators to search for 
complementary and alternative therapies and drugs.  
Many traditional Chinese medicines have long been used 
in the treatment of various cardiovascular diseases, such as 
coronary heart disease, heart stroke and myocardial infarction, 
and some of them are effective in promoting blood circulation, 
removing blood stasis and supplementing vital energy[5, 6]. 
Although these medicines display considerable therapeutic 
effects with low toxicity, little is known about their primary 
active ingredients and detailed pharmaceutical mechanisms. 
Nevertheless, these traditional Chinese medicines, dating back 
2000 years, have been regarded as valuable sources to screen 
potential drugs for the treatment of cardiovascular diseases.
With the rapid development of technology, numerous con-
stituents in traditional Chinese medicines have been isolated 
and structurally determined[7].  Abundant steroid-like com-
pounds, structurally similar to cardiac glycoside, have been 
found in many Chinese medicines used for promoting blood 
circulation[8, 9].  It is likely that these steroid-like compounds 
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are responsible for the therapeutic effects of these medicines 
via the same molecular mechanism triggered by effective inhi-
bition of Na+/K+-ATPase.  On the other hand, no appreciable 
contents of steroid-like compounds are found in danshen 
(Salvia miltiorrhiza), a well-known Chinese herb tradition-
ally regarded as an effective medicine for promoting blood 
circulation[10].  Instead, magnesium lithospermate B (MLB), the 
major soluble ingredient in danshen, is assumed to be respon-
sible for the therapeutic effect by inhibiting Na+/K+-ATPase in 
a manner comparable to that of cardiac glycosides.
This review summarizes recent research on Na+/K+-ATPase 
inhibitory potency of some active ingredients identified in 
the Chinese medicines used for promoting blood circula-
tion.  Molecular modeling and docking of these compounds 
to Na+/K+-ATPase resolve at molecular level the difference 
in their inhibitory potency.  Potential usage of these active 
ingredients as inhibitors of Na+/K+-ATPase in the brain for the 
treatment of ischemic stroke is also discussed.  
Structure and function of Na+/K+-ATPase
Na+/K+-ATPase, a P-type ATPase also known as sodium 
pump, is an active transport system of sodium and potassium 
ions that is highly conserved in all animal cells.  It commonly 
consumes 20%–30% of the adenosine triphosphate (ATP) 
energy generated in animal cells at rest to actively transport 
three Na+ out of and two K+ into cells[11].  The X-ray crystal 
structure of Na+/K+-ATPase recently resolved[12–14] shows 
that it is composed of three subunits (α, β and γ subunits) 
with distinct properties[15-17]; and the α catalytic subunit, a 112 
kDa protein, contains sites important for ATP binding and 
phosphorylation as well as ion occlusion (Figure 1A) and an 
ouabain-binding site (Figure 1B), the primary binding site for 
many pharmacological agents, such as cardiac glycosides, that 
affect pump activity[18].
Physiological functions of Na+/K+-ATPase have been 
deduced from its role as an ion pump.  Specifically, the abil-
ity of Na+/K+-ATPase to establish and maintain ion gradients 
makes it essential for the generation and maintenance of elec-
trical membrane potentials, which are necessary for neuronal 
excitability, transmission[19] and cardiac muscle contraction[20]. 
Na+/K+-ATPase also generates the Na+ gradient that is critical 
for the reabsorption of sodium ion and water from the glom-
erular filtrate in the nephron[21] and absorption of fluid from 
the lungs and intestine[22].  It can also drive secondary active 
co-/countertransporters, which are coupled to the gradient 
of extracellular to intracellular Na+ concentration, such as the 
sodium glucose cotransporter and the Na+/Ca2+ exchanger[23]. 
In addition, recent findings have suggested additional signal-
ing modes of action of Na+/K+-ATPase[24–26], implicating its 
regulation of several important cellular processes and high-
lighting potential therapeutic roles of its inhibitors (such as 
cardiac glycosides) in various diseases.
Inhibition of Na+/K+-ATPase by cardiac glycosides 
leading to a positive inotropic effect
Cardiac glycosides, such as ouabain and digoxin, are a diverse 
family of naturally derived compounds that bind to and 
inhibit Na+/K+-ATPase.  While they show considerable struc-
tural diversity, all members of this family share a common 
steroidal framework, regarded as the pharmacophoric moiety 
responsible for the activity of these compounds[27].  Generally, 
this steroid core is double-substituted with an unsaturated 
lactone ring at position 17 and a sugar portion at position 3; 
and this lactone moiety of cardiac glycosides is critical for 
their potent inhibition of Na+/K+-ATPase.  Although the sugar 
moiety does not greatly influence their biological activity, the 
addition of sugars to the steroid core affects the pharmacody-
namic and pharmacokinetic profile of each glycoside[28].  
Cardiac glycosides have been in clinical use for many years 
for the treatment of congestive heart failure and cardiac 
arrhythmia, and the mechanism of their positive inotropic 
effect is well characterized.  According to the most widely 
accepted molecular mechanism responsible for the therapeutic 
effect of cardiac glycosides, they act through reversible inhibi–
tion of Na+/K+-ATPase in the membrane of heart muscle 
Figure 1.  (A) Crystal structure of ouabain binding to the extracellular 
pocket of shark rectal gland Na+/K+-ATPase (PDB code 3A3Y) α subunit[17]. 
Amino acid residues of Na+/K+-ATPase α subunit are shown in ribbon 
structure, and ouabain in scaled ball and stick.  K+ binding sites are 
shown in purple balls.  (B) Enlarged diagram without the membrane 
bilayer shown in the blue box of (A). 
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cells[29, 30].  In human heart, inhibition of the Na+/K+-ATPase 
leads to the accumulation of intracellular sodium ion, which 
decreases the sodium gradient across the membranes of car-
diac muscle cells.  This reduced sodium gradient in turn limits 
the activity of the Na+/Ca2+ exchanger in the cell membrane, 
which normally uses the sodium gradient for energy in the 
extrusion of calcium ion[31].  Each cardiac action potential 
is thus followed by elevated levels of residual intracellular 
calcium ion, and the net effect of which is to strengthen suc-
cessive heart contractions[32].  In this way, inhibition of the 
Na+/K+-ATPase by cardiac glycosides produces beneficial 
effects in patients with congestive heart failure.  However, 
severe side effects and narrow therapeutic index of cardiac 
glycosides have apparently limited their clinical applica-
tions[29].
Steroid-like compounds in Chinese medicines for 
promoting blood circulation and their inhibitory potency 
on Na+/K+-ATPase 
Many Chinese medicinal products traditionally used in the 
treatment of cardiovascular diseases seem to achieve their 
therapeutic effects via promotion of blood circulation.  A 
number of steroid-like compounds, such as triterpenoids, 
steroids and saponins, have been found in Chinese medici-
nal products used for promoting blood circulation (Table 1), 
and regarded as the active ingredients responsible for their 
therapeutic effects[33–64].  In light of the structural similarity 
between the core structure of these steroid-like compounds 
and the steroidal framework of cardiac glycosides, we pro-
pose that some of these medicines may possess therapeutic 
effects via inhibition of Na+/K+-ATPase by their steroid-like 
compounds[65].  Some of the steroid-like compounds listed in 
Table 1 are commercially available and thus subjected to Na+/
K+-ATPase inhibition assay (Figure 2).  The results show that 
all examined steroid-like compounds found in Chinese medi-
cines for promoting blood circulation displayed more or less 
inhibitory potency on Na+/K+-ATPase.  Among these steroid-
like compounds, bufalin (structurally almost equivalent to 
ouabain) exhibits significantly higher inhibitory potency (IC50 
value around 1 μmol/L) than the others while ginsenoside 
Rh2, ursolic acid and oleanolic acid are relatively moderate 
inhibitors of Na+/K+-ATPase with IC50 values around 50–100 
μmol/L.  Based on the experimental observation of inhibitory 
potency of steroid-like compounds on Na+/K+-ATPase, the 
therapeutic effects of many cardiac Chinese medicines may 
be partly attributed to various steroid-like compounds that 
promote blood circulation via the same molecular mechanism 
triggered by cardiac glycosides, that is, accentuating the force 
of myocardial contraction by elevating calcium concentration 
via the inhibition of Na+/K+-ATPase.
Inhibition of Na+/K+-ATPase by MLB, a non-steroid 
compound, leading to the therapeutic effect of danshen 
Danshen, the dried roots of medicinal plant Salvia miltiorrhiza, 
is one of the most popular Chinese medicines widely used in 
many medicinal preparations and formulae taken by people 
in several Asian countries.  Traditionally it is regarded as 
an effective herb for promoting blood circulation, removing 
blood stasis, relieving pain, stimulating menstrual discharge, 
and relaxing the mind.  Therefore, danshen has also been 
extensively used in the treatment of coronary heart disease, 
myocardial infarction, heart failure, menstrual disorders, and 
Table 1.  Steroid-like compounds in Chinese medicines used for the promotion of blood circulation. 
       Compound                                                                 Chinese medicinal sources                                                                                          References 
 
 Bufalin The dried venom of Bufo bufo gargarizans Cantor or B bufo melanostictua Schneider 33, 34
 Ginsenoside Rh2 The dry root of Panax ginseng or P notoginseng F H Chen 35–37
 Ursolic acid Whole plant of Prunella vulgaris L with dry flowers 38, 39
 Oleanolic acid Whole plant of Prunella vulgaris L with dry flowers 38, 39
 Saikosaponin A The dry root of Bupleurum chinense DC or B scorzonerifolium Willd 40, 41
 Cholic acid The dried bile of Ursus arctos Linnaeus or Selenarctos thibetanus G Cuvier 42, 43
 Sarsasapogenin The dry root of Anemarrhena asphodeloides Bge 44
 Polygalacic acid The dry root of Platycodon grandiflorum (Jacq) A DC 45
 Jujuboside B The mature seeds of Ziziphus jujube Mill var spinosa (Bunge) Hu ex H F Chou 46
 Glycyrrhizin The root of Glycyrrhiza uralensis Fisch -  G inflata Bat or G glabra L 47, 48
 Astragaloside III The dry root of Astragalus membranaceus (Fisch) Bge or var mongholicus (Bge) Hsiao 49
 Betulinic acid The dried root cortex of Paeonia suffruticosa 50
 Inokosterone The dry root of Achyranthes bidentata Blume 51
 Dehydrocorydaline The tuber of Corydalis yanhusuo W T Wang 52, 53
 Rhynchophylline The hook of Uncaria rhynchophylla (Miquel) Jacks 54, 55
 Hirsutine The hook of Uncaria rhynchophylla (Miquel) Jacks 56–58
 Cucurbitacin D The fruit of Trichosanthes kirilowii Maxim or T rosthornii Harms 59, 60
 β-Boswellic acid The oleogum resin of Boswellia carterii Birdwood 61
 Isolimonoic acid The fruit of Citrus aurantium L 62
 β-Sitosterol The rhizome of Sparganium stoloniferum Buch-Ham 63
 Pachymic acid The sclerotium of Poria cocos (Schw) Wolf 64
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other cerebrovascular diseases[66].  Ingredients in danshen 
are mainly divided into water-soluble and lipid-soluble com-
pounds.  Although some lipid-soluble constituents in this 
herb, such as tanshinones, have been conventionally consid-
ered the active ingredients[67, 68], the major water-soluble com-
ponent MLB, a derivative of caffeic acid tetramer, recently has 
also been demonstrated to possess several medicinal effects, 
such as vasodilating, antihypertensive, antioxidative, and free 
radical scavenging activities[69–73].  MLB possesses a relatively 
rigid structure due to the formation of salt bridges between 
Mg2+ and the four oxygen atoms of carboxyl groups from the 
four caffeic acid fragments.  
In spite of being a non-steroid compound, MLB possesses 
potent inhibition on Na+/K+-ATPase in vitro[74].  The molecular 
organization and configuration of MLB in the 3D structure is 
somewhat similar to ouabain, a cardiac glycoside with a rigid 
steroid backbone (Figure 3A), although they are totally dif-
ferent compounds with distinct molecular weights (584.65 for 
ouabain and 740.67 for MLB).  Based on experimental observa-
tion and theoretical modeling, we propose that MLB acts as 
the active component responsible for the cardiac therapeutic 
effect of danshen by the same molecular mechanism triggered 
by cardiac glycosides, ie, inhibition of Na+/K+-ATPase (Figure 
3B).  In agreement with this proposal, the intracellular Ca2+ 
Figure 2.  (A) Chemical structures of ouabain and 11 steroid-like 
compounds found in Chinese medicinal products used for the 
promotion of blood circulation.  (B) Inhibition of porcine Na+/K+-
ATPase by 0.1 mmol/L of ouabain and the selected 11 steroid-like 
compounds.  Data represent mean±SEM of 5 replicates.  bP<0.05, 
cP<0.01 vs control group (CON: deionized water only).  (Adopted 
and modified from Figures 1 and 2 of Chen et al, Acta Pharmacol 
Sin 2010; 31: 696–702).
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levels of SH-SY5Y neuroblastoma cells treated with MLB are 
substantially elevated in a manner similar to that observed in 
cells treated with ouabain[75].  The elevated Ca2+ levels seem to 
be supplied by both extracellular influx through the Na+/Ca2+ 
exchanger and intracellular release from endoplasmic reticu-
lum.  
Cell toxicity caused by cardiac glycosides at high concentra-
tions has been noticed and blamed to their putative triggering 
of several signaling cascade responses that lead to cell death[76]. 
In contrast, MLB is generally regarded as an antioxidant 
without notable toxicity[74].  Similar results were found in our 
studies: severe cell toxicity accompanied with dendritic shrink 
was observed in SH-SY5Y cells treated with ouabain, but not 
in those treated with MLB[75].  Therefore, we surmise that MLB 
has a great potential, with extensive clinical trials, to become a 
safer drug than cardiac glycosides.
Molecular modeling: the binding mode of potential 
inhibitors to Na+/K+-ATPase
Molecular modeling and docking of steroid-like compounds 
and MLB to the α subunit of Na+/K+-ATPase revealed the 
observed difference in their Na+/K+-ATPase inhibition at 
molecular level.  The drastic difference observed in the inhibi-
tory potency of these active ingredients is ascribed mainly 
to the number of hydrogen bonds (H-bonds) and partially 
to the strength of hydrophobic interaction between the com-
Figure 3.  (A) Chemical structures of ouabain and 
MLB.  The 3D structures of ouabain and MLB (in dark 
background) were displayed using RasWin Molecular 
Graphics Windows Version 2.6.  Gray, red, and green 
colors represent C, O, and Mg2+ atoms, respectively.  (B) 
Proposed molecular mechanism responsible for the 
therapeutic effects of cardiac glycosides, ginsenosides, 
MLB, and other steroid-like compounds in cardiac cells. 
Step 1: Inhibiting the cellular exchange of Na+ and K+ by 
drugs binding to Na+/K+-ATPase.  Step 2: Accumulation 
of Na+ in the intracellular space due to the inhibition of 
Na+/K+-ATPase activity.  Step 3: Promotion of the cellular 
exchange of Na+ and Ca2+ via the Na+/Ca2+ exchanger 
system.  Step 4: Increasing the intracellular Ca2+ 
concentration owing to the activation of the Na+/Ca2+ 
exchanger system.  Step 5: The elevated intracellular 
Ca2+ concentration leads to an increased inotropism and 
accentuates the force of myocardial contraction.  (Adopted 
from Figure 1 and the cover page of Tzen et al, Acta 
Pharmacol Sin 2007; 28: 609–15).
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pounds and residues around the deep cavity close to the two 
K+ binding sites of Na+/K+-ATPase (Figure 4).  As expected 
from structural similarity, the interaction of bufalin with the 
binding pocket of Na+/K+-ATPase nearly matched to that of 
ouabain reported previously[16] with the unique lactone ring 
penetrating deeply into the cavity close to two K+ binding 
sites.  For ouabain, three H-bonds are formed between the lac-
tone ring and Ile328 and Ala330 of Na+/K+-ATPase, and two 
H-bonds between the hydroxyl group at C-14 and Thr804 of 
Na+/K+-ATPase.  In contrast, one H-bond is formed between 
the lactone ring of bufalin and Ala330 of Na+/K+-ATPase, and 
two H-bonds between the hydroxyl group at C-14 of bufalin 
and Thr804 of Na+/K+-ATPase.  Two H-bonds are formed 
between the hydroxyl groups at C-12 and C-20 of ginsenoside 
Rh2 and Asn129 and Thr804 of Na+/K+-ATPase, respectively. 
Strong hydrophobic interaction is found between the lac-
tone ring of ouabain or bufalin and six hydrophobic residues 
(Ile327, Ile328, Val329, Ile787, Phe790, and Ile807) around the 
deep cavity of Na+/K+-ATPase.  A hydrophobic interaction 
between the alkyl group of ginsenoside Rh2 and the same six 
hydrophobic residues of Na+/K+-ATPase is also found.  Only 
one H-bond is formed between the carboxyl group of ursolic 
acid and Ile322 of Na+/K+-ATPase, and a moderate hydropho-
bic interaction is found between the ring E of ursolic acid and 
four hydrophobic residues (Ile327, Val329, Phe790, and Ile807) 
of Na+/K+-ATPase.  On the whole, no H-bond is formed 
between those steroid-like compounds with weak inhibitory 
potency and the binding pocket of Na+/K+-ATPase[65].  How-
ever, hydrophobic interaction of similar strength is observed 
between the hydrophobic steroidal core of all 12 steroid-
like compounds examined and 8 other hydrophobic residues 
(Leu132, Tyr315, Ile322, Phe323, Ile325, Phe793, Ile794, and 
Leu802 located in the upper portions of the figures) around 
the binding pocket of Na+/K+-ATPase.
Three H-bonds are formed between the hydroxyl group 
at C-4 position of MLB and Lys912 (forming two H-bonds) 
and Glu915 (forming one H-bond) of Na+/K+-ATPase, one 
H-bond between the carbonyl group at C-9 position of MLB 
and Thr804 of Na+/K+-ATPase, and one H-bond between 
the hydroxyl group at C-4 position of MLB and Leu110 of 
Na+/K+-ATPase.  Similar to the hydrophobic steroidal core of 
ouabain, the four aromatic rings of MLB form strong hydro-
phobic interaction with hydrophobic residues (Leu132, Tyr315, 
Ile322, Phe323, Ile325, Phe793, Ile794, and Leu802) around the 
binding pocket of Na+/K+-ATPase.
Effects of different sugar attachments to ginsenosides 
on Na+/K+-ATPase inhibitory potency 
Ginsenosides are triterpenoidal saponins that have a com-
mon four ring hydrophobic steroid-like structure with various 
sugar moieties attached mostly at the C-3, C-6, or C-20 position 
(Figure 5).  To date, more than 80 ginsenosides have been iso-
lated from over ten Panax taxa, and most of them are derived 
from four types of aglycones: protopanaxadiol, protopanaxa-
triol, oleanolic acid, and ocotillol[77].  Several biological activi-
ties, such as neuroprotective effects, antitumour activity, and 
cardiac therapeutic effects, have been documented for many 
ginsenosides[78, 79].  Ginsenosides have also been regarded as 
the active ingredients in many Chinese herbs, for instance, 
ginseng and sanqi (the roots of Panax ginseng and Panax notog-
inseng), two well-known traditional Chinese herbs commonly 
used for the treatment of coronary heart disease and cerebral 
vascular disease[80–82].
Based on experimental observation and theoretical model-
ing, the therapeutic effects of ginseng and sanqi in promoting 
blood circulation should be at least partly attributed to the 
effective inhibition of Na+/K+-ATPase by ginsenosides[83], such 
as ginsenoside Rh2.  However, different sugar moieties in gin-
senosides affect their inhibitory potency on Na+/K+-ATPase. 
In our study, ginsenosides with sugar moieties attached only 
to the C-3 position of the steroid-like structure, equivalent 
to the sugar position in cardiac glycosides, possess inhibi-
tory potency on Na+/K+-ATPase.  However, their inhibitory 
potency is significantly reduced or completely abolished when 
a monosaccharide was linked to the C-6 or C-20 position of the 
steroid-like structure; the inhibitory potency is lost completely 
when the monosaccharide is replaced by a disaccharide mol-
ecule at either positions.  Molecular modeling and docking 
show that sugar attachment to the C-6 or C-20 position of the 
steroid-like structure apparently causes steric hindrance to the 
entrance of ginsenosides into the extracellular binding pocket 
of the Na+/K+-ATPase α subunit, and thus greatly reduces or 
completely abolishes their inhibitory potency.
Paradoxically, most ginsenosides found in ginseng and sanqi 
do not seem to be competent inhibitors of Na+/K+-ATPase 
due to their sugar attachment to the C-6 or C-20 position of 
the steroid-like structure.  Nevertheless, ginsenosides might 
act as prodrugs, as they tend to be metabolized to their active 
forms by intestinal bacterial deglycosylation after oral admin-
istration[84].  Generally, the metabolites, easily absorbed by the 
intestines due to an increase of hydrophobicity after deglyco-
sylation, might display the same or different pharmacologi-
cal actions in comparison with their parent compounds[85]. 
Therefore, the cardiac therapeutic effects of ginseng and sanqi 
could very possibly be attributed to the effective inhibition of 
Na+/K+-ATPase by the metabolized ginsenosides, with sugar 
moieties attached only to the C-3 position of the steroid-like 
structure.
Combinational usage of danshen and sanqi for the 
treatment of cardiovascular diseases
In contrast with Western medicines, combinational usage 
of traditional Chinese medicines with similar or different 
therapeutic effects is a common practice.  Currently, several 
commercial products for cardiovascular diseases comprise 
mainly danshen and sanqi in variable ratios, mostly with dan-
shen as the major and sanqi the minor constituents[86].  The 
active ingredients in danshen and sanqi for cardiac therapeu-
tic effects are MLB and ginsenosides, respectively.  MLB, a 
polyphenolic compound, is metabolized within a few hours 
after consumption[87].  In contrast, it takes a couple of days to 
metabolize the steroid-like ginsenosides in human body[88, 89]. 
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Figure 4.  Detai led molecular interactions 
between the extracellular binding pocket of 
Na+/K+-ATPase and ouabain, bufalin, ginsenoside 
Rh2, ursolic acid, or MLB. (Left panels)  Modeling 
is displayed for ligand compounds, ouabain, 
bufalin, ginsenoside Rh2, ursolic acid, and MLB 
binding to the extracellular pocket of Na+/K+-
ATPase α subunit.  Amino acid residues around 
the binding pocket of Na+/K+-ATPase are shown in 
ribbon structure, and ligand compounds in stick 
structure.  (Right panels) Amino acid residues of 
Na+/K+-ATPase close to ligand compounds (ball-
and-stick structure) are shown in line structure. 
Green box or oval represents one or two hydrogen 
bonds formed between Na+/K+-ATPase and ligand 
compounds.  (Adopted and modified from Figure 6 
of Chen et al, Acta Pharmacol Sin 2010; 31: 696–
702 and Figure 5 of Chen et al, Acta Pharmacol 
Sin 2010; 31: 923–9).
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In light of our recent studies, we rationalize that the combina-
tional usage of danshen and sanqi for the treatment of cardio-
vascular diseases takes the advantages of the non-toxic and yet 
strong Na+/K+-ATPase inhibitory potency of MLB to relieve 
the symptoms promptly and the moderate Na+/K+-ATPase 
inhibitory potency of ginsenosides to provide a relatively 
long-term basal therapeutic effect.  
Inhibition of Na+/K+-ATPase and its potential neuro-
protection 
In brain cells, approximately half of all energy is spent for 
the active exchange of cytosolic sodium for extracellular 
potassium, a process carried out by Na+/K+-ATPase for the 
maintenance of transmembrane ionic gradients for all mam-
malian cells[90–92].  As the brain’s primary consumer of ATP, 
Na+/K+-ATPase is particularly vulnerable to ATP depletion 
commonly observed in ischemic stroke.  This vulnerability 
suggests that pharmacological inhibition of the Na+/K+-AT-
Pase in brain cells should further compromise ATP-depleted 
neurons.  Indeed, there is accumulating evidence that inhibit-
ing the brain Na+/K+-ATPase can actually provide neuropro-
tection in the context of ischemia[93].  
Cardiac glycosides, being potent inhibitors of Na+/K+-
ATPase, have been demonstrated to provide neuroprotec-
tion against ischemic stroke in a cortical brain slice-based 
compound screening platform[94].  Moreover, it has been 
hypothesized that blockade of Na+/K+-ATPase may provide 
neuroprotective effect in ischemia-reperfusion through ATP 
conservation and modulating intracellular calcium levels just 
as the cardiac glycosides do in the heart contraction cycle[93]. 
Similar neuroprotective effects have also been documented for 
ginsenosides against ischemic stroke, and some of the results 
were observed using the same brain slice assay model[95–99]. 
Oleanolic acid, a steroid-like compound and moderate inhibi-
tor of Na+/K+-ATPase, also displayed neuroprotective effect 
against focal cerebral ischemic injury[100].  Furthermore, the 
same phenomenon was observed when we examined the neu-
roprotective effect of MLB against ischemic stroke in a similar 
brain slice assay model[74].  Taken together, these experimental 
data support that inhibiting Na+/K+-ATPase may provide neu-
roprotection in the context of ischemia as well as other neuro-
degenerative conditions.  It is more than likely that effective 
inhibitors of Na+/K+-ATPase in the brain are potential drugs 
for the treatment of ischemic stroke.
Conclusions and perspectives 
With a history of at least 2000 years, traditional Chinese 
medicines have long been regarded as precious resources for 
screening new drugs.  Our recent studies have shown that 
steroid-like compounds in many Chinese medicines used for 
promoting blood circulation display more or less inhibitory 
potency on Na+/K+-ATPase, and may thus provide the thera-
peutic effects of corresponding medicines via the same molec-
ular mechanism triggered by cardiac glycosides.  Except bufa-
lin in ChanSu, steroid-like compounds in traditional Chinese 
medicines used for promoting blood circulation are expected 
to exert less severe side effects than cardiac glycosides.  Nev-
ertheless, side effects have to be expected of a continuous con-
sumption of these steroid-like compounds for a long period 
of time.  In contrast, MLB, the non-steroid active ingredient 
responsible for the cardiac therapeutic effect of danshen by 
effective inhibition of Na+/K+-ATPase, is generally regarded 
as a non-toxic antioxidant without apparent adverse effects. 
Therefore, we believe that MLB is of great potential to replace 
cardiac glycosides for the treatment of congestive heart fail-
ure, provided it undergoes necessary clinical trials.  Moreover, 
searching from traditional Chinese medicines for additional 
antioxidant polyphenolic compounds possessing inhibitory 
potency on Na+/K+-ATPase may lead to the discovery of novel 
drugs for the treatment of cardiovascular diseases without 
side effects.
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